$VYGR

Voyager Therapeutics (NASDAQ:VYGR) reported second-quarter results. Shares rose 7.9% to $3.27. Revenues were 31% below analyst predictions, while losses of $0.40 per share were 20% smaller than expected. Analysts now forecast 2026 revenue of $46.0m (up from $39.3m) and losses of $1.87 per share, with the consensus price target unchanged at $14.89.

Voyager Therapeutics, Inc. (VYGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Voyager Reports Second Quarter 2026 Financial and Operating Results - VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 - - Ended Q2 2026 with cash position of $149 million, runway into 2028 - LEXINGTON, Mass., August 6, 2026 -- Voyager Therape

Ahead of Q2 earnings, Morgan Stanley kept a constructive view on aerospace and defense, citing resilient commercial demand, improving aircraft production, and durable aftermarket needs. It noted Boeing 737 MAX at 47 aircraft per month. For defense, it argued a $1.1T FY2027 base budget is underestimated. It downgraded Loar and TransDigm, cut CAE and Voyager, and adjusted price targets for multiple firms.

On Jim Cramer’s “Mad Money” (June 30), he told a 23-year-old caller to buy Voyager Therapeutics (NASDAQ:VYGR) based on a long time horizon, noting the company is still unprofitable. Voyager has Q1 FY26 revenue of $2.59M (vs $8.79M consensus) and net loss of $27.94M; cash $171.66M. Analysts rate VYGR 11 Buys with ~$14.89–$15 average targets.

Benzinga reports analyst actions and stock moves for several companies. Bernstein initiated GE Vernova coverage (Outperform) with a $1,206 target. Ultra Clean was reiterated/raised by Oppenheimer to $115; shares rose 9.1%. Voyager Technologies rose 6.9% after FDA clearance for VY1706. TE Connectivity target raised to $230; Symbotic fell; Enphase rose after joining Open Compute Project.

Voyager Therapeutics, Inc. (VYGR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false --12-31 0001640266 0001640266 2026-06-09 2026-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date

The article says SpaceX’s upcoming IPO will add to a growing set of public companies tied to the space economy. It cites renewed focus on U.S.-China lunar efforts and SpaceX’s Mars plans and “Golden Dome” missile-shield plans. It lists competitors across launch, satellites, imagery, and defense, noting SpaceX had 80%+ of global launches last year and 10,000+ Starlink satellites in orbit.

Voyager Therapeutics Inc (VGYR) has seen a modest 30% rise in its stock over the past year, but analysts predict a potential 250% surge in the next 12 months due to advancements in its drug programs. The company recently presented positive preclinical data for its Alzheimer's disease gene therapy, VY1706, which reduced tau protein in non-human primates by up to 64% without adverse events. Voyager plans to seek FDA authorization for human clinical trials of VY1706 in Q2 2026 and expects efficacy data for its VY7523 anti-tau antibody program in the latter half of the year.

Voyager Therapeutics Inc. announced that its CFO, Nathan Jorgensen, will resign from his position, effective May 8, 2026. The announcement was made via a brief news item from Refinitiv.

Voyager Therapeutics presented its strategic vision at the Stifel 2026 Virtual CNS Forum, focusing on its "year of tau" with ambitious plans to advance tau-targeting assets and novel capsid technology. The company intends to file an IND for its tau knockdown gene therapy in Q2 2026 and aims to demonstrate proof of concept for its capsids and shuttle technology through clinical trials next year. Voyager is pursuing partnerships with major pharmaceutical companies like Neurocrine, Novartis, and AstraZeneca to leverage external expertise and resources for its programs.